< 1 minute read
Dec. 16, 2021

GSK852: a BET BD2 inhibitor

GSK852

1000x BD2-selective BET bromodomain inh. orally available in dog rational design from prior lead Journal of Medicinal Chemistry GlaxoSmithKline, Stevenage, UK

drughunter.com
Drug Hunter Team

The GSK BET BD2 inhibitor, GSK852 , is one of a series of BD2-targeting compounds published last month by GSK (see a fragment-based approach here , a DEL screening approach here , and a pincolinamide molecule here ). Each of these campaigns is impressive and educational in different ways, and the collective GSK BD2 effort is a tour de force [...]

Loading...

twitterlinkedinemail

Other molecules you may be interested in